

## High Sensitivity Glutamate Biosensor

**Track Code:** 2018-LEE-68334

**Categories:**

- Biomedical Engineering
- Biotechnology

**Keywords:**

- Biotechnology
- Neurodegenerative Disease
- Spinal Cord Injury

Glutamate excitotoxicity (GE) is a dynamic process by which neurons are damaged due to excessive amount of glutamate in the cell. It is hypothesized by scientists that glutamate excitotoxicity is a secondary injury that can occur after spinal cord injury (SCI). The limited knowledge of the role of glutamate in secondary injury has limited the development of therapeutics for GE. In 2016, the National Spinal Cord Injury Statistical Center reported 300,000 people currently live with spinal cord injury (SCI) in the United States. SCI is a debilitating illness that often leaves patients with limited mobility. The lifetime healthcare cost per patient can range from \$1,200,000 to \$5,000,000 per patient. Current bioanalytical techniques such as nuclear resonance imaging have low spatiotemporal resolution and poor sensitivity for determining glutamate levels. Since glutamate excitotoxicity is dynamic in nature and can progress over time, it is crucial that the glutamate diagnostic tools possess high spatiotemporal resolution and sensitivity of glutamate.

Researchers at Purdue University have developed a biosensor with superior sensitivity for measuring glutamate levels in hopes to better understand GE. In in vitro studies, it was found that the newly developed biosensor exhibited 6 times higher glutamate sensitivity in comparison to glutamate biosensors fabricated in other labs. The biosensor had high selectivity for glutamate with a detection limit 14  $\mu\text{M}$ .

**Advantages:**

- High sensitivity for glutamate
- High selectivity for glutamate
- High stability

**Potential Applications:**

- Early diagnosis of SCI

**People:**

- Lee, Hyowon (Project leader)
- Nguyen, Tran N. H

### **Intellectual Property:**

**Application Date:** January 6, 2022  
**Type:** NATL-Patent  
**Country of Filing:** United States  
**Patent Number:** (None)  
**Issue Date:** (None)

**Application Date:** July 6, 2020  
**Type:** PCT-Patent  
**Country of Filing:** WO  
**Patent Number:** (None)  
**Issue Date:** (None)

**Application Date:** July 7, 2019  
**Type:** Provisional-Patent  
**Country of Filing:** United States  
**Patent Number:** (None)  
**Issue Date:** (None)

**Application Date:** July 6, 2018  
**Type:** Provisional-Patent  
**Country of Filing:** United States  
**Patent Number:** (None)  
**Issue Date:** (None)

### **Contact OTC:**

Purdue Office of Technology Commercialization  
The Convergence Center  
101 Foundry Drive, Suite 2500  
West Lafayette, IN 47906

Phone: (765) 588-3475  
Fax: (765) 463-3486  
Email: [otcip@prf.org](mailto:otcip@prf.org)